Dasvir Tablet

Introduction

Dasvir Tablet 60 mg is an antiviral medication used in the treatment of chronic hepatitis C virus (HCV) infection. It is a direct-acting antiviral (DAA) that specifically targets the hepatitis C virus to help clear the infection from the body.

Uses

Dasvir Tablet 60 mg is used in combination with other antiviral agents to treat chronic hepatitis C infection. It is typically used in combination with sofosbuvir, another antiviral medication. It is not used alone and is indicated for patients with specific genotypes of HCV.

Brand Name	Dasvir
Type	Tablet
Weight	60 mg
Generic	Daclatasvir
Manufacturer	UniMed UniHealth Pharmaceuticals Ltd.
Available in	English বাংলা

Mechanism of Action

Dasvir Tablet 60 mg works by inhibiting the hepatitis C virus (HCV) NS5A protein, which is essential for viral replication and assembly. By blocking this protein, daclatasvir prevents the virus from replicating and spreading.

How Long Does It Take to Work?

The antiviral effects of daclatasvir can be observed within weeks of starting treatment. However, it is crucial to complete the full course of therapy as prescribed, which typically lasts 12 to 24 weeks, to achieve a sustained virologic response (SVR) and effectively clear the virus.

Absorption

Dasvir Tablet 60 mg is well-absorbed after oral administration. Its bioavailability is not significantly affected by food, and it reaches peak plasma concentrations within 1 to 4 hours.

Route of Elimination

Dasvir Tablet 60 mg is primarily metabolized in the liver by cytochrome P450 enzymes. It is excreted mainly through the feces, with a minor amount eliminated through the urine.

Dosage

Recommended Dosage: The recommended dose of Daclatasvir is 60 mg once daily, to be taken orally with or without meals.

Daclatasvir must be administered in combination with other medicinal products. The Summary of Product Characteristics for the other medicinal products in the regimen should also be consulted before initiation of therapy with Daclatasvir. Recommended regimens and treatment duration are provided in table below:

For the regimen of Daclatasvir+Sofosbuvir, data for 12-week treatment duration are available only for treatment-naïve patients with genotype 1 infection. For Daclatasvir+Sofosbuvir with or without Ribavirin, data are available for patients with advanced liver disease (≥F3) without cirrhosis. The recommended use of Daclatasvir+Sofosbuvir in genotype 4 is based on extrapolation from genotype 1. For the regimen of Daclatasvir+Peginterferon alfa + Ribavirin, data are available for treatment-naïve patients.

The dose of Ribavirin, when combined with Daclatasvir, is weight-based (1,000 or 1,200 mg in patients <75 kg or ≥75 kg, respectively).
Dose modification, interruption and discontinuation: Dose modification of Daclatasvir to manage adverse reactions is not recommended. If treatment interruption of components in the regimen is necessary because of adverse reactions, Daclatasvir must not be given as monotherapy.
There are no virologic treatment stopping rules that apply to the combination of Daclatasvir with Sofosbuvir.
Treatment discontinuation in patients with inadequate on-treatment virologic response during treatment with Daclatasvir, Peginterferon alfa and Ribavirin.

Dose recommendation for concomitant medicines:

Strong inhibitors of cytochrome P450 enzyme 3A4 (CYP3A4): The dose of Daclatasvir should be reduced to 30 mg once daily when coadministered with strong inhibitors of CYP3A4.
Moderate inducers of CYP3A4: The dose of Daclatasvir should be increased to 90 mg once daily when coadministered with moderate inducers of CYP3A4.
Missed doses: Patients should be instructed that, if they miss a dose of Daclatasvir, the dose should be taken as soon as possible if remembered within 20 hours of the scheduled dose time. However, if the missed dose is remembered more than 20 hours after the scheduled dose, the dose should be skipped and the next dose taken at the appropriate time.

The usual recommended dose of daclatasvir is 60 mg taken orally once daily. The exact dosage may vary based on the patient's genotype, treatment history, and concurrent medications. It is essential to follow the dosing instructions provided by the healthcare provider.

Administration

Dasvir Tablet 60 mg is administered orally in the form of tablets. It should be taken with or without food, typically once daily. It is crucial to take it at the same time each day to maintain consistent blood levels.

Side Effects

Common side effects of daclatasvir may include:

Headache
Fatigue
Nausea
Diarrhea
Insomnia

Toxicity

High doses of daclatasvir or misuse may lead to increased risk of side effects or toxicity. Symptoms of overdose are not well-documented but may include severe fatigue, nausea, or headache. In case of suspected overdose, seek medical attention immediately.

Precautions

Precautions include:

Monitoring for drug interactions, as daclatasvir may interact with other medications.
Assessing liver function regularly, particularly in patients with pre-existing liver conditions.
Ensuring adherence to the full course of therapy to prevent the development of drug resistance.

Interaction

Dasvir Tablet 60 mg may interact with other medications, including:

Antiepileptics (e.g., carbamazepine, phenytoin)
Rifampin
HIV protease inhibitors
Some antifungals and antibiotics

These interactions can affect the efficacy of daclatasvir or increase the risk of side effects.

Disease Interaction

Dasvir Tablet 60 mg should be used with caution in patients with:

Severe hepatic impairment, as it is primarily metabolized in the liver.
Renal impairment, although it is less commonly affected by renal function.

Drug Interaction

Dasvir Tablet 60 mg may interact with drugs that affect liver enzymes, including:

CYP3A4 inducers and inhibitors
Other antiviral medications

Careful monitoring and dose adjustments may be necessary to avoid adverse effects or reduced efficacy.

Food Interactions

Dasvir Tablet 60 mg can be taken with or without food, as food does not significantly affect its absorption. However, patients should follow the specific guidance provided by their healthcare provider.

Pregnancy Use

Dasvir Tablet 60 mg is classified as a Category B drug for pregnancy. It is not known to cause harm to an unborn baby, but its use should be carefully considered in pregnant women. Consult a healthcare provider for appropriate recommendations.

Lactation Use

It is not known whether daclatasvir is excreted in breast milk. The decision to use daclatasvir while breastfeeding should be made in consultation with a healthcare provider, considering the benefits and risks.

Acute Overdose

In case of acute overdose, seek immediate medical attention. Treatment is symptomatic and supportive. There is no specific antidote for daclatasvir overdose.

Contraindication

Dasvir Tablet 60 mg is contraindicated in patients with:

Severe hypersensitivity to daclatasvir or any component of the formulation.
Severe hepatic impairment unless specifically guided by a healthcare provider.

Use Direction

Take daclatasvir exactly as prescribed. Do not skip doses or discontinue the medication without consulting your healthcare provider, as this may lead to treatment failure or resistance.

Storage Conditions

Store daclatasvir tablets at room temperature, away from moisture and heat. Keep out of reach of children and do not use after the expiration date.

Volume of Distribution

The volume of distribution of daclatasvir is not well-documented but is generally understood to be extensive as it is widely distributed in body tissues.

Half Life

The half-life of daclatasvir is approximately 12-15 hours, allowing for once-daily dosing. This can vary depending on individual patient factors and liver function.

Clearance

Dasvir Tablet 60 mg is primarily cleared by the liver. The clearance rate can be influenced by liver function and concurrent medications. Regular monitoring is recommended to ensure proper drug levels and efficacy.

See in details version Dasvir Tablet 60 mg also Dasvir Tablet 60 mg in bangla